Trial Profile
A Phase IIIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Efficacy Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza From Otherwise Healthy Patients to Household Contacts
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Baloxavir-marboxil (Primary)
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Registrational; Therapeutic Use
- Acronyms Centerstone
- Sponsors Roche
- 31 Mar 2024 Planned End Date changed from 30 Apr 2024 to 11 May 2024.
- 31 Mar 2024 Planned primary completion date changed from 30 Apr 2024 to 11 May 2024.
- 31 Jan 2024 This trial has been Completed in France, According to European Clinical Trials Database record.